Haylie Day
Family · Greenbrier, ARNPI 1366119752
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 203 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$558
- Novo Nordisk$411
- Amgen$383
- Lilly USA, LLC$354
- AstraZeneca$339
- Otsuka America Pharmaceutical, Inc.$262
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,917100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $558 |
| Novo Nordisk | 29 | $411 |
| Amgen | 23 | $383 |
| Lilly USA, LLC | 21 | $354 |
| AstraZeneca | 19 | $339 |
| Otsuka America Pharmaceutical, Inc. | 13 | $262 |
| Pfizer | 15 | $253 |
| Bayer | 9 | $162 |
| Phathom Pharmaceuticals, Inc. | 1 | $153 |
| Scynexis, Inc. | 1 | $140 |
| Bioventus LLC | 1 | $136 |
| Gilead | 1 | $115 |
| Boehringer Ingelheim | 4 | $63 |
| Biohaven Pharmaceuticals, Inc. | 1 | $62 |
| Exact Sciences | 4 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $57 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Shield Therapeutics Inc | 2 | $46 |
| GSK | 2 | $40 |
| UCB, Inc. | 1 | $30 |
| Noven Therapeutics, LLC | 2 | $30 |
| Cycle Pharmaceuticals Inc | 1 | $30 |
| Axsome Therapeutics, Inc. | 2 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Ardelyx, Inc. | 1 | $24 |
| Antares Pharma, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,917 in reported general payments places this provider in the 90th percentile of 2,103 family providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 18 | $216,754 |
| GlatopaGlatiramer Acetate | 18 | $36,768 |
| OzempicSemaglutide | 22 | $20,973 |
| Teriflunomide | 30 | $14,875 |
| Dalfampridine ErDalfampridine | 64 | $14,413 |
| TrulicityDulaglutide | 12 | $13,444 |
| MounjaroTirzepatide | 13 | $13,130 |
| JardianceEmpagliflozin | 15 | $12,066 |
| Baclofen | 146 | $3,697 |
| Gabapentin | 122 | $1,588 |
| Tizanidine Hcl | 112 | $1,399 |
| Duloxetine Hcl | 39 | $759 |
| Oxybutynin Chloride ErOxybutynin Chloride | 23 | $747 |
| Carbamazepine | 28 | $587 |
| Levothyroxine Sodium | 81 | $585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $354 | $26,57325 claims |
| Novo NordiskOzempic | $411 | $20,97322 claims |
| Boehringer IngelheimJardiance | $63 | $12,06615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,103 family providers in Arkansas.
Other family in Greenbrier
- Jarrod JerryGreenbrier$11K
- Lauren BlansettGreenbrier$8K
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.